Mild Cognitive Impairment
Conditions
Keywords
mild cognitive impairment, blood amyloid beta, home-based cognitive monitoring
Brief summary
This study is an observational study to confirm usefulness of a home-based cognitive monitoring in non-demented patients with high-risk of dementia
Detailed description
We prospectively enroll subjects who were diagnosed as mild cognitive impairment based on neuropsychological tests battery, brain MRI, and routine blood labs including thyroid function tests, vitamine B12 & folate levels, and syphilis screening to rule out other secondary causes of dementia. We undergo peripheral blood-based amyloid beta levels and regular home-based cognitive monitoring (every 3 months) to investigate whether amyloid-positive MCIs progress rapidly using home-based cognitive monitoring during 6 months.
Interventions
DIAGNOSTIC_TESThome-based cognitive monitoring
a newly developed home-based cognitive monitoring (about 3-5 minutes per test; total score ranges from 0\ 30; higher score indicates better cognition)
Sponsors
Asan Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* persistent cognitive complaints * aged 50 years old or older * below -1.0 standard deviation in any domain of detailed neuropsychological tests battery named SNSB (Seoul neuropsychological screening battery) * no ADL (activities of daily living) limitation * subjects who agreed to participate
Exclusion criteria
* dementia patients * other structural brain disorders such as hydrocephalus, hemorrhage, or tumors * other neurological disease such as Huntington's disease, Parkinson's disease, or epilepsy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| home-based cognitive monitoring score | 3 months (at baseline, 3 months from baseline, 6 months from baseline) | a 3-5 minutes brief cognitive testing (range 0\ 30, higher score means better outcome) using telephone |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hippocampal atrophy grade | at baseline | baseline brain MRI markers for hippocampal atrophy using Scheltens' visual rating scale (range 0\ 4, higher score means more hippocampal atrophy) |
| Number of lacunes | at baseline | number of lacunes using manual counting on brain MRI (no limit) |
| Number of microbleeds | at baseline | number of microbleeds using manual counting on brain MRI (no limit) |
Countries
South Korea
Contacts
Primary ContactYunJeong Hong, MD,PhD
Outcome results
None listed